Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Core Insights - The webinar focuses on Capricor Therapeutics' Phase 3 trial, HOPE-3, which is assessing the investigational product deramiocel for treating Duchenne muscular dystrophy [1]. Group 1: Company Overview - Capricor Therapeutics is represented by its CEO Linda Marban, Chief Medical Officer Michael Binks, and Chief Development Officer Mark Awadalla during the webinar [2]. Group 2: Event Structure - The presentation includes a Q&A session at the end, allowing participants to submit questions via a chat function [3]. - The webinar is recorded and will be available on PPMD's website for future reference [3].